Cosmos Health (COSM) announced that its wholly owned subsidiary, Cana Laboratories S.A., has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL pessaries, further expanding its pipeline of pharmaceutical products. Under the terms of the agreement, Cana will manufacture MYCOFAGYL, a combination of Metronidazole and Nystatin in pessary dosage form. The product will be supplied in packs of 10 units. The Company anticipates manufacturing and delivering 3 million pessaries per year. MYCOFAGYL is widely prescribed for the treatment of vaginal infections, including
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COSM:
- Cosmos Health launches Sky Premium Life food supplements brand
- Cosmos Health files to sell 78.64M shares of common stock for holders
- Cosmos Health’s Sky Pharma sign distribution agreement with Scientific Pharmacy
- Cosmos makes initial $1M ethereum purchase under digital asset treasury strategy
- Cosmos Holdings Secures $8M Convertible Note Agreement